VLX600|cas:327031-55-0|西域试剂

VLX600,98.17%

产品编号：Bellancom-12406| CAS NO：327031-55-0| 分子式：C₁₇H₁₅N₇| 分子量：317.35

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-12406	￥550.00	杭州北京（现货）
Bellancom-12406	￥900.00	杭州北京（现货）
Bellancom-12406	￥1900.00	杭州北京（现货）
Bellancom-12406	￥3200.00	杭州北京（现货）
Bellancom-12406	￥5500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

VLX600

产品介绍

VLX600 是氧化磷酸化 (OXPHOS) 的铁螯合抑制剂。VLX600 导致线粒体功能障碍，并导致向糖酵解的强烈转变。VLX600 对恶性细胞表现出选择性的细胞毒活性，并诱导自噬 (autophagy)。具有抗癌活性。

生物活性

VLX600 is an iron-chelating inhibitor of oxidative phosphorylation (OXPHOS). VLX600 causes mitochondrial dysfunction and induces a strong shift to glycolysis. VLX600 displays selective cytotoxic activity against malignant cell and induces autophagy. Anticancer activity.

体外研究

VLX600 (6 μM; 72 hours) induces an autophagic response.
VLX600 is cytotoxic to HCT116 spheroids. VLX600 induces a HIF-1α-dependent glycolytic response. VLX600 inhibits oxygen consumption in HCT116 cells. VLX600 inhibits phosphorylation of the mTOR downstream effectors 4EBP1 and p70-S6K by an HIF-1α-independent mechanism. VLX600 preferentially leads to decreased ATP levels in cancer but not normal cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	HCT116, HT29, SW620, HT8, DLD and RKO cells
Concentration:	0.1, 1, 10, 100μM
Incubation Time:	72 hours
Result:	Inhibited the proliferation of these cells.

Western Blot Analysis

Cell Line:	HCT116 cells
Concentration:	6 μM
Incubation Time:	72 hours
Result:	LC3-II was induced.

体内研究
(In Vivo)

VLX600 (16 mg/kg; i.v.; every third day for 16 days) shows anti-tumor activity in human tumor xenografts.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NMRI nu/nu mice (HCT116 and HT29 colon cancer xenografts)
Dosage:	16 mg/kg
Administration:	Intravenously; every third day for 16 days
Result:	Anti-tumor activity was observed in both HCT116 and HT29 colon cancer xenografts.

体内研究

VLX600 (16 mg/kg; i.v.; every third day for 16 days) shows anti-tumor activity in human tumor xenografts.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NMRI nu/nu mice (HCT116 and HT29 colon cancer xenografts)
Dosage:	16 mg/kg
Administration:	Intravenously; every third day for 16 days
Result:	Anti-tumor activity was observed in both HCT116 and HT29 colon cancer xenografts.

体内研究

VLX600 (16 mg/kg; i.v.; every third day for 16 days) shows anti-tumor activity in human tumor xenografts.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NMRI nu/nu mice (HCT116 and HT29 colon cancer xenografts)
Dosage:	16 mg/kg
Administration:	Intravenously; every third day for 16 days
Result:	Anti-tumor activity was observed in both HCT116 and HT29 colon cancer xenografts.

性状

Solid

溶解性数据

In Vitro:

DMSO : 25 mg/mL (78.78 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.1511 mL	15.7555 mL	31.5110 mL
5 mM	0.6302 mL	3.1511 mL	6.3022 mL
10 mM	0.3151 mL	1.5755 mL	3.1511 mL

请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: 2.08 mg/mL (6.55 mM); Clear solution; Need ultrasonic

此方案可获得 2.08 mg/mL (6.55 mM) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。